OUR LATEST NEWS
December 4, 2023
OXFORD BIOMEDICA SIGNS AGREEMENT TO ACQUIRE ABL EUROPE FROM INSTITUT MERIEUX
October 24, 2023
HOW TO CHOOSE THE RIGHT CDMO PARTNER
October 19, 2023
KEY CMC CONSIDERATIONS FOR THE DEVELOPMENT OF YOUR VIRUS / VIRAL-VECTOR PROGRAMS
October 5, 2023
UNLOCKING SUCCESS IN GENE THERAPIES: THE CRUCIAL ROLE OF QTPP AND FINDING THE RIGHT PARTNER TO DEPLOY THE QBD APPROACH
September 21, 2023
OXFORD BIOMEDICA AND INSTITUT MERIEUX ENTER INTO EXCLUSIVE NEGOTIATIONS FOR THE PROPOSED ACQUISITION OF ABL EUROPE
September 18, 2023
ASEPTIC PROCESS OF VIRAL VECTOR-BASED VACCINES – KEY ASPECTS TO CONSIDER BEFORE CLINICAL MANUFACTURING
August 29, 2023
PROCESS CHARACTERIZATION OF VIRAL VECTORS: APPROACH IN CDMO CONTEXT
July 18, 2023
OVERCOMING OBSTACLES IN DOWNSTREAM BIOPROCESSING OF AAV-BASED GENE THERAPY PRODUCTS
May 4, 2023
WORKING TOWARDS AN AAV PLATFORM IN 2023: CHALLENGES, THREATS & OPPORTUNITIES
March 24, 2023